UNSPSC 51182212: Mepitiostane

This classification denotes an antiestrogen with the molecular formula C25H40O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O00404969K, chemically known as 5-alpha-androstane, 2-alpha,3-alpha-epithio-17-beta-(1-methoxycyclopentyloxy)- but generally known as mepitiostane, which bears US NIH Compound Identifier 30605. European Medicines Agency schedules Mepitiostane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08753MIG.

UNSPSC 51182212 Mepitiostane is a Commodity code covering specific pharmaceutical active ingredients and preparations supplied through state and local cooperative purchasing vehicles. State and local governments procure under this code primarily through multistate cooperative agreements that consolidate demand across participating jurisdictions, establishing framework contracts with pharmaceutical manufacturers and distributors to supply generic and branded pharmaceutical products at negotiated rates. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code and operates as a cooperative vehicle serving multiple states including Oregon. Vendors responding to opportunities under this code must meet rigorous compliance and operational standards, including cGMP and Drug Supply Chain Security Act certification, maintenance of contractual relationships with authorized wholesalers equipped with chargeback systems, and submission of detailed product specifications by National Drug Code, SKU, UPC, strength, dosage form, and manufacturing location. Insurance requirements are substantial—workers' compensation, $5,000,000 commercial general liability per occurrence, $2,000,000 network security and privacy liability, and $2,000,000 professional liability—and all products must comply with FDA requirements and maintain a minimum six-month shelf life.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, demonstrates the current market activity under this code. The procurement specifies three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and awards multiple framework contracts for a two-year term effective July 1, 2026, with optional extensions. Evaluation weights pricing competitiveness (75 percent), fixed pricing for the contract term (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and administrative format compliance (5 percent). Vendors must agree to a 3 percent administrative fee on all purchases and accept performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. No specific set-aside designations or disadvantaged-enterprise restrictions are documented in the available solicitation materials.